Explore the latest research, expert guidance, and practical tips on oral immunotherapy, allergen management, and living allergy-free.
A comprehensive look at the evidence behind sublingual immunotherapy (SLIT) — from landmark clinical trials to modern meta-analyses — and why leading allergists now consider it a first-line treatment for allergic rhinitis.
New studies show that sublingual immunotherapy can reduce pet allergy symptoms by up to 60%. Here's what the research says about building tolerance to Fel d 1 and Can f 1.
Timing matters. Research from the Journal of Allergy and Clinical Immunology shows that starting SLIT 3-4 months before pollen season leads to significantly better outcomes.
A systematic review in the Cochrane Database found SLIT to be significantly safer than subcutaneous immunotherapy, with no reported fatalities across 60+ clinical trials.
The FDA-approved ODACTRA tablet proved SLIT's efficacy for dust mites. New research shows multi-allergen sublingual formats may deliver comparable results with greater convenience.
A meta-analysis of 42 randomized controlled trials found SLIT to be both safe and effective in pediatric patients, with adverse events limited to mild oral itching in most cases.
Science-backed sublingual immunotherapy delivered to your door. No clinic visits, no injections.
Shop Sprays